

Fig. 1. *Enterobacter cloacae* 0206.

2. Materials and methods

2.1. Materials

Enterobacter cloacae,
 st t s t fi t s t t s t
 t C G M C t C t C t C t
 (CGMCC). Ass ts ts N J B t C . Lt.
 s (FFA) t N J , C L .

2.2. Preparation of EPS

(t^{t} , 2013). B₁₀³ (10%), t_s, 2.5%; t_c, 0.5%; M_{0.4}⁷H₂O, 0.05%) at 30°C for 48 h. The yield was 5.0% (1).

At t - t - t t t - s t t (11,000)
 20 - t ss t 50°C, t t 3 . t 95% EtOH
 - s - t t s t t t t t t t
 11,000 15 t z t t s ss st t
 - ! t t ! z t t s t s t t
 - s s - t t t (t , 1965). t s t t
 - z t t st t t t t t (8000 14,000,
 - t) t t t t t t t t
 s s t t

2.3. *Animals*

M KKA C57BL/6J t t 6 s
st (H z ,C).

t \downarrow 1s 12 t/12 60±10% t
 t \downarrow 22±2°C t ss t t s t .
 t \downarrow t z t t ! t s t s t s
 1 . A t t A t c C t t s
 t , t t t st .

2.4. Experimental design

KKA ss t s A s t
 KK s t s t 2 t s C57BL/6J
 s t ts, KKA s s t s t s t
 st s t s t s s t t t t
 (n=8). F 8 s t KKA t E
 (200 / t) 6 s. st t (C57BL/6J)
 t s st t t st t t t t
 st) s o B s G s M t (t 12
 7 s. B t s s t s t s t A
 t t t t t s s st t t t
 s fi t s t A s s s t t
 t t t s s t s s t t t
 s t , s t s s t s t t
 t st t -80°C.

2.5. Oral glucose tolerance test (OGTT)

2.6. Blood biochemical measurement

At t 12, t 6 s t t t t t t t t t t t t t t
 st t z t s s s s t t t t t t t t t t t t
 s s s s t t t t t t t t t t t t t t t t
 ss s s s s s s s s s s s s s s t t ss
 (ELI A) t. L s s s s s C, G, LDL
 st t t t st (HDL) s
 t t z F tt (FFA) t t
 B s t t t t t t t t t t t t t t t t t
 st t t s

2.7. Liver glycogen and hexokinase measurement

At t 42 s, t s fi , s
 - s t ! t s t ss t . G
 s s s t t t t . A t t
 HK s s s t s 6 s t t s
 t t . s ts(N J ts s B
 I st t , N J , C).




Fig. 2. E-t-E vs t(A)-st(B) for KKA (n=8).

2.8. Real-time PCR

t NA - s t - t t t ss s t I
 z - t(I t L s C s , CA A) I
 NA - t t - s t fi t N D ND 1000s
 t t t . C ss s s s v8B G
 z t 18 (t O s M st ; A B s st s).
 G6 , GK, H L, A GL, FA C 1α t s ts t
 t t s C t t L tC 1.5(M st C
 E t - 4 E , G). t t t C
 - - - s s t t (95°C 30s,
 1 40 s 95°C 5s 60C 30s). C s
 s : G6 : 5' AA C C C C GG G G GC 3' (); 5'
 GC G AG AG CGG G CC 3' (s); GK: 5' CC C G AA
 GGC ACG AAG A 3' (); GK: 5' GAG AAG CC CAC GA G
 G 3' (s); A GL: 5' GAG CCC CGG GG GGA ACA AGA
 3' (); A GL: 5' AAA AGG GG GG GCA GGA G A AGG 3'
 (s); H L: 5' GCC GG GAC GC GAA AG GG 3' ();
 H L: 5' CGC GCA GA GGG AGC AAG AGG 3' (s); FA : 5'
 A C C G GAA CGA GAA CAC GA C 3' (); FA : 5' AGA
 GAC G G CA C C C G GAC 3' (s); C 1α: 5' G G CC
 AAG A C G GCA G C 3' (); C 1α: 5' CA GGG A C
 CA AAG CA A 3' (s); 18 : 5' CGG ACA CGG ACA GGA G
 ACA 3' (); 18 : 5' CCA GAC AAA CG C C CAC CAA C A
 3' (s). t ss s ss ss t Ct

A s_ s t t t t - - - s

2.9. Western blotting assay

100 t ss s | ss , t
 t s t t s t 14,000 x g 15 t 4°C
 t t t s t st t -80°C. t
 t t s t ts t BCA t ss t
 t t s t fl s t D AGE t tt
 t t t t s t AM K, t pAM K, t G t2
 t t t1. t s t t t ECL s st .

3. Results

3.1. Effect of EPS on body weight and fasting blood glucose levels

s F .2.D t t t t t KKA s
t t t E t t t s. At t t
t t E ,t t s s f i t (p<0.05)
t t t KKA , s st t t
E t t t tt s s s t ss




Fig. 3. E t E LOG KKA (D t - ss s - s ± D (n=5).
* p<0.05


Ass F .2, s t s t t KKA
 s fi t t s t s t KKA
 st E 42 s t s fi t t s t KKA
 (p<0.05) st s t t t t KKA

3.2. Effect of EPS on the oral glucose tolerance test

At 42 s E t ts, s t - ! s
 t t t t s s t OG s t .
 F .3s st - ! s t s t OG
 (2 s / t). t KKA ! t t
 s s s fi t st t C57BJ/6L .
 s s st t t ss fi t (p<0.05)
 E t t t t KKA t t t t t
 t t t t E s - - - - t t
 s s s .

3.3. Effect of EPS on serum insulin and lipids levels in KKAY mice

3.4. Effect of EPS on hexokinase and glycogen content in the liver of KKAY mice



3.5. Expressions of glucose and lipid metabolism genes and proteins

fi t ! ! - !s E !
 s s !s s, s tt - t ts t
 s t !s t s t s -
 t s !t tss .F st , - t ss !s
 GK, G6 , H L, A GL, C 1α, FA s ! - tt C .As
 t F .6A, t ss ! GK ss !fi !t
 t (p<0.05) t t E , t ss !
 G6 s (p<0.05) t t KKA
 As s F .6B, t s s fi t ! s (p<0.05) i
 A GL, H L C 1 α ss t t ss KKA
 s t t E - t t t KKA
 FA NA ss ! s ! t 30% (p< 535 /G 4539.




Fig. 4. Effects of EPS on serum levels of (A) insulin, (B) triglycerides, (C) total cholesterol, (D) LDL cholesterol, (E) HDL cholesterol and (F) FFA ($p < 0.05$). Values are expressed as mean \pm SD ($n = 6$); (a) $p < 0.05$ vs Lean; (b) $p < 0.05$ vs Control.




Fig. 5. Effects of EPS on liver glycogen (A) and hexokinase (B) ($p < 0.05$). Values are expressed as mean \pm SD ($n = 6$); (a) $p < 0.05$ vs Lean; (b) $p < 0.05$ vs Control; (c) $p < 0.05$ vs EPS.




Fig. 6. E t E t s t t s t KKA .
 (A) t ss GK G6 ;(B) t ss A GL,H L,C 1 α
 FA ($n=3$, $s \pm D$; * $p < 0.05$, s
 G t 2 AM K nAM K t t KKA);(C) ss .

Acknowledgment

A s st -s s \ t s - ! - st - s \ C \ M (N . CA
36).

References

- B, S, N., J. Ost, C. G., & E. (2001). Islet transplantation. *Diabetes*, 50, 1449–1454.

B, G., & G. (2002). Fatty acids and diabetes. *European Journal of Clinical Investigation*, 32, 14–23.

C, t, C., & A. J. (2009). GC levels in AM K. Current Opinion in Lipidology, 20, 98–105.

C, B., C., . . . , K., C., t, L, M, . . . & H. (2005). I, tt, s, t, 2, t, s, t, s, s. *American Journal of Physiology Endocrinology and Metabolism*, 289, E151–E159.

C, . . . , L, M., & M. H. (2008). Ast, s, s, s: A t, t, t, t, s, t, NOD. *Experimental and Clinical Endocrinology & Diabetes*, 116, 468–474.

- Mazzola, A. A. (1997). *Hypothetical models of cellular and molecular life sciences*, 53, 131–140.
- , & G., A. J. (2008). *Type 2 diabetes mellitus. Contemporary endocrinology*. —, N., & —, M. (2004). AM: *Antidiabetic agents*: C A: *Antidiabetic agents*. —, E., G., E. B., M., K., L., L., B., J., & J., C. L. (2006). A GL: *Antidiabetic agents*: *EMBO Reports*, 7, 106–113.
- , K., & —. (2012). A GL: *Antidiabetic agents*: *The Indian Journal of Medical Research*, 136, 451–472.
- Tucker, A. M. (1965). *Carbohydrate Chemistry*, 5, 5–6.
- Trivedi, G., & K., B. E. (2009). AM: *Ketone bodies*. *Physiological Reviews*, 89, 1025–1078.
- Wang, H., Li, F., Fan, K., Guo, G., & Guo, J. (2009). *Antidiabetic agents*: *Pleurotus ostreatus*. *Bioresource Technology*, 100, 1682–1686.
- Wang, J. G., Wang, L. A., Guo, H., & Chen, K. C. (2009). *Antidiabetic agents*: *Ganoderma lucidum*. *Journal of Agricultural and Food Chemistry*, 57, 10565–10572.
- , L., Q., —, K. F., F., & —. (2012). MDG: *Ophiopogon japonicus*: *Antidiabetic agents*: *13K/Antidiabetic agents*: *KKA*: *Antidiabetic agents*. *Journal of Ethnopharmacology*, 143, 347–354.
- , F., —, H., & —. (2012).